Supplementary appendix
|
|
- William Brooks
- 6 years ago
- Views:
Transcription
1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med 2018; published online March 28.
2 1 Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, activecontrolled, trial Peter M A Calverley, Antonio R Anzueto, Kerstine Carter, Lars Grönke, Christoph Hallmann, Christine Jenkins, Jadwiga Wedzicha, Klaus F Rabe Supplementary material Supplementary methods Prespecified subgroup analyses It was prespecified to examine the primary endpoint in subgroups according to baseline medications (LAMA, LABA, inhaled corticosteroid) and baseline characteristics (sex, race, smoking history, and GOLD stage). Definition of actual and planned treatment periods The primary endpoint was analyzed during the actual treatment period, defined as the time from first dose of medication until 1 day after the last dose of medication. This was also the period used for exacerbation and other endpoints. The on-treatment period is defined as the time from first dose of medication until 21 days after last dose, and was used for adverse event analysis. The planned study period is the full planned 360 days of treatment after first dose plus 21 days of follow-up (for vital status sensitivity analysis), and the planned treatment period is defined as 360 days of treatment plus 1 day for wash-out (for exacerbation sensitivity analysis). Definition of exacerbation start and end The onset of exacerbation was defined as the onset of first recorded symptom that was identified by the investigator to be due to an exacerbation; the end of the exacerbation was determined by the investigator. Rationale for the higher significance level Although the conventional scientific threshold for a significant difference between treatments is at the 5% level (p<0 05), pharmaceutical regulators require stronger proof of an effect if the results of a single treatment trial are to be included in a product label. The trial sponsors were able to support one large study and requested that we set the significance level for the primary outcome at the 1 % level (p<0 01) such that the results could be added to the product label. Supplementary results When planning the study sample size, we considered that there would be a dispersion parameter in the negative binomial model that would range between 0 8 and 0 9. This was primarily based on the assumptions used in the SPARK study, 1 where the dispersion value had been assumed to be 0 625, but we increased the value to allow for the baseline adjustments reported in that study. The observed dispersion value in our data was much larger than expected at There were significantly more patients who withdrew from the study while taking tiotropium alone than with tiotropium/olodaterol. We investigated whether there were differences in the baseline characteristics of patients withdrawing and those who continued (Supplementary Table 4), as well as running a stepwise regression analysis to determine factors predictive of discontinuation (Supplementary Table 5). The variables identified closely resemble those prospectively adjusted for in several other studies of treatment interventions on exacerbation rates in COPD patients. 1 4 Therefore, we undertook a further analysis, applying the adjustments done by others to our data as shown in Supplementary Table 6. Given the encouraging findings, we performed further analyses based on two additional models (Supplementary Table 6). In all cases, the adjusted model led to a change in the rate ratio of exacerbations, and led to a p value close to or below the 1% level we originally expected. These changes were accompanied by a reduction in the dispersion parameter to the levels we had originally expected to see.
3 2 Supplementary Tables Supplementary Table 1. Inclusion and exclusion criteria. Inclusion criteria Informed consent Exclusion criteria A significant disease other than COPD (that may put the patient at risk, influence the results of the study, or cause concern regarding patient s ability to participate) Male or female patients, aged 40 years Diagnosis of COPD and stable airway obstruction with post-bronchodilator FEV 1 <60% of predicted normal and a post-bronchodilator FEV 1/FVC <0 7 (historical spirometric data within the previous 3 months may be used) At least one moderate or severe exacerbation in the previous 12 months requiring treatment with systemic corticosteroids and/or antibiotics and/or hospitalization Clinically relevant abnormal baseline hematology, blood chemistry, or creatinine >2x upper limit of normal Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma Symptomatically stable: no evidence of COPD exacerbation requiring use of either antibiotics and/or steroids, and no evidence of change in their usual COPD medication 4 weeks prior to screening A diagnosis of thyrotoxicosis, life-threatening cardiac arrhythmia, known active tuberculosis, any malignancy unless free of disease for at least 5 years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed), clinically relevant bronchiectasis, or severe emphysema requiring endobronchial interventions within 6 months prior to screening Current or ex-smokers with a smoking history of >10 pack-years Patients must be able to perform all trial-related procedures at the investigator discretion A history of myocardial infarction within 6 months of screening History of cystic fibrosis Patients must be able to inhale medication in a competent manner from the Respimat inhaler, and from an MDI in the opinion of the investigator A history of significant alcohol or drug abuse
4 3 Patients who have undergone thoracotomy with pulmonary resection Patients being treated with oral or patch beta-adrenergics Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than 4 weeks on a stable dose), or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day Patients being treated with antibiotics for any reason (not limited to exacerbation infection) within 4 weeks of screening Patients being treated with PDE4 inhibitors within 3 months of screening visit Patients who have taken an investigational drug within 1 month or 6 half-lives (whichever is greater) Patients with known hypersensitivity to beta-adrenergic and/or anticholinergics drugs, BAC, EDTA, or any other component of the Respimat inhalation solution Pregnant or nursing women, and women of child-bearing potential not using a highly effective method of birth control Patients who have previously been randomized in this study or are currently participating in another study Patients who are unable to comply with pulmonary medication restrictions prior to randomization BAC, benzalkonium chloride; COPD, chronic obstructive pulmonary disease; EDTA, ethylenediaminetetraacetic acid; FEV 1, forced expiratory volume in 1 second; FVC, forced vital capacity; MDI, metered-dose inhaler; PDE4, phosphodiesterase-4.
5 4 Supplementary Table 2. Frequency of reasons for screen failures noted in 5 patients (patients could be excluded for more than one reason). Number of Reason for screen failure screen failures, n 672 Failure to meet FEV 1 and FEV 1/FVC criteria 49 Clinically relevant abnormal baseline hematology, blood chemistry, or creatinine 42 Not symptomatically stable 27 Significant disease other than COPD 25 Lack of pulmonary function text data 25 Failure to meet exacerbation history criteria 21 Treated with oral corticosteroid at unstable doses or doses in excess of the equivalent of 10 mg prednisone per day 19 Malignancy 16 Unable to perform all trial-related procedures 15 Treated with oral or patch beta-adrenergics 15 Current diagnosis of asthma 13 Have undergone thoracotomy with pulmonary resection 13 Treated with antibiotics within 4 weeks 12 History of significant drug or alcohol abuse 12 Unable to comply with pulmonary medication restrictions prior to randomization 8 Currently treated with PDE4 inhibitors within 3 months 6 Clinically relevant bronchiectasis 5 Life-threatening cardiac arrhythmia 5 Failure to meet smoking criteria COPD, chronic obstructive pulmonary disease; FEV 1, forced expiratory volume in 1 second; FVC, forced vital capacity; PDE4, phosphodiesterase-4.
6 5 Supplementary Table 3. Adverse events leading to death (adjudicated) in all randomized patients during the whole trial (causes of death with frequency 0 2%). Variable Tiotropium/olodaterol (N=3,939) Tiotropium (N=3,941) Patients with adjudicated death no. (%) 110 (2 8) 123 (3 1) Cardiac disorders 7 (0 2) 6 (0 2) General disorders and administration site 33 (0 8) 32 (0 8) conditions Death 11 (0 3) 10 (0 3) Sudden cardiac death 11 (0 3) 11 (0 3) Sudden death 11 (0 3) 11 (0 3) Infections and infestations 6 (0 2) 12 (0 3) Pneumonia 3 (0 1) 8 (0 2) Neoplasms 14 (0 4) 12 (0 3) Malignant lung neoplasm 7 (0 2) 8 (0 2) Respiratory 36 (0 9) 52 (1 3) COPD 35 (0 9) 52 (1 3)
7 6 Supplementary Table 4. Differences in baseline characteristics in patients who discontinued early and those who completed the trial. Characteristic Concomitant therapy at baseline n (%) Discontinued early (N=1,138) Completed as planned (N=6,742) Total (N=7,880) LABA only 32 (2 8) 225 (3 3) 257 (3 3) LAMA only 65 (5 7) 650 (9 6) 715 (9 1) ICS only 33 (2 9) 167 (2 5) 200 (2 5) LABA/ICS 210 (18 5) 1,826 (27 1) 2,036 (25 8) LAMA/ICS 17 (1 5) 149 (2 2) 166 (2 1) LAMA/LABA 147 (12 9) 792 (11 7) 939 (11 9) LAMA/LABA/ICS 578 (50 8) 2,554 (37 9) 3,132 (39 7) None 56 (4 9) 379 (5 6) 435 (5 5) Exacerbation history in previous year n (%) 1 moderate exacerbation 541 (47 5) 3,850 (57 1) 4,391 (55 7) 2 moderate or 1 severe exacerbation FEV 1 percent predicted - mean (SD) GOLD Stage n (%) 597 (52 5) 2,890 (42 9) 3,487 (44 3) 41 1 (12 6) 45 1 (29 4) 44 5 (27 7) (26 8) 2,479 (36 8) 2,784 (35 3) (51 9) 3,448 (51 1) 4,039 (51 3) (20 7) 757 (11 2) 992 (12 6) FEV 1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; SD, standard deviation.
8 7 Supplementary Table 5. Variables identified as predictive of discontinuation using a stepwise regression. Variable Chi square Region < Screening post-bronchodilator FEV 1 % predicted < Age < Baseline CAT score < Number of exacerbations leading to hospitalization in the year prior to randomization Sex Number of exacerbations treated with steroids and antibiotics in the year prior to randomization Inhaled corticosteroid use at baseline a a Any inhaled corticosteroid use at baseline (yes/no). CAT, COPD Assessment Test; FEV 1, forced expiratory volume in 1 second.
9 8 Supplementary Table 6. Annualized rate of moderate or severe exacerbations analyzed using multiple covariates models similar to those used in previous COPD trials. Number of events Study model was based on Tiotropium Tiotropium/ olodaterol Rate ratio (Tiotropium/olodaterol vs tiotropium) 95% CI p value Dispersion parameter SPARK/FLAME a 2,960 2, HERMES b 2,968 2, TRINITY/TRILOGY c 2,968 2, a Smoking status, baseline inhaled corticosteroid, GOLD stage, region, CAT score (replacing baseline symptom score), exacerbations treated with antibiotics/steroids history in previous year (replacing 1-year history of exacerbations). Because FEV 1 reversibility was not measured, it could not be included in the model; b age, sex, smoking status, baseline LABA/inhaled corticosteroid, region, percent predicted post-bronchodilator FEV 1; c treatment, region, severity of airflow limitation, and smoking status as effects, and exacerbations treated with antibiotics/steroids in previous year. CAT, COPD Assessment Test; CI, confidence interval; FEV 1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LABA, long-acting beta-agonist.
10 9 Supplementary Figure 1. Time to treatment discontinuation. CI, confidence interval.
11 10 Supplementary Figure 2. Annualized rate of moderate or severe exacerbations by baseline therapy (A) and baseline characteristics (B). CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; T/O, tiotropium and olodaterol combination; Tio, tiotropium.
12 11 References 1 Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1(3): Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389(10082): Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus longacting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388(10048): Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374(9691):
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationRoflumilast: Οι κλινικές μελέτες
Roflumilast: Οι κλινικές μελέτες Επαμεινώνδας Ν. Κοσμάς Δ/ντής Πνευμονολογικού Τμήματος Νοσοκομείου Metropolitan PDE4 PLAYS AN IMPORTANT ROLE IN INFLAMMATION PDE4 inhibition P P P PDE4 P Adapted from Rabe
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationBlood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,
More informationAclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A15-06 Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aclidiniumbromid/Formoterol
More informationTo describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.
Educational aims To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype. To describe the spectrum of pharmacological and non-pharmacological interventions
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationRoflumilast for the treatment of respiratory disease: review of the Phase II and III trials
Roflumilast for the treatment of respiratory disease: review of the Phase II and trials Clin. Invest. (2011) 1(10), 1413 1419 Roflumilast (Daxas [EU], Daliresp [USA]) is the first phospho diesterase 4
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationRevefenacin (TD-4208) Phase 3 Efficacy Results
Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered
More informationNew Medicines Committee Briefing July Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD
Ultibro is to be reviewed for use within: New Medicines Committee Briefing July 2017 Glycopyrronium bromide/indacaterol (Ultibro ) for maintenance treatment of adults with stable COPD Summary: Primary
More informationNuovi farmaci in sviluppo per la BPCO
PNEUMOLOGIA 2018 MILANO, 14 16 GIUGNO 2018 CENTRO CONGRESSI PALAZZO DELLE STELLINE Nuovi farmaci in sviluppo per la BPCO Leonardo M. Fabbri, MD, FERS Professor of Respiratory and Internal Medicine, University
More informationRoflumilast with long-acting b 2 -agonists for COPD: influence of exacerbation history
Eur Respir J 211; 3: 553 56 DOI: 1.113/9319.1771 CopyrightßERS 211 with long-acting b 2 -agonists for COPD: influence of exacerbation history E.D. Bateman*, K.F. Rabe #,", P.M.A. Calverley +, U.M. Goehring
More informationNew Medicine Recommendation Trimbow
New Medicine Recommendation Trimbow Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler for treatment of COPD Recommendation: GREEN (restricted) Restriction: Triple therapy
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationCOPD is a significant cause of mortality
RESPIRATORY CLINICAL FOCUS Comparing the range and costs of COPD treatments in primary care Practice nurses should familiarise themselves with the many products available for the management of chronic
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationReport of the COPD7 Conference Conference Report Sponsored by
Report of the COPD7 Conference 2010 Conference Report Sponsored by Report of the COPD7 Conference 2010 CONTENTS Burden of COPD Pages 3-4 Current challenges in COPD management Pages 5-6 Overcoming challenges
More informationBrand Name: Daliresp. Generic Name: roflumilast. Manufacturer: Forest Pharmaceuticals, Inc.
Brand Name: Daliresp Generic Name: roflumilast 3, 4, 5 Manufacturer: Forest Pharmaceuticals, Inc. 1, 2,4,5,7 Drug Class: Second Generation Phosphodiesterase 4 (PDE 4) inhibitor Labeled Uses: prophylaxis
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationOriginal. Showa Univ J Med Sci 30 2, , June 2018
Showa Univ J Med Sci 30 2, 159 174, June 2018 Original Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary
More informationClass Update: Asthma / COPD Medications
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life
Breathtaking science Developing respiratory drugs to improve health and quality of life Wedbush PacGrow Healthcare Conference New York City, August 2018 NASDAQ VRNA www.veronapharma.com Forward-Looking
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 May 2011 Examination of the file for the proprietary medicinal product included for a period of 5 years by the
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationNew Drug Evaluation: Olodaterol oral inhalation solution (Striverdi Respimat)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationRandomized double-blind controlled trial of roflumilast at acute exacerbations of
Page 1 of 12 AJRCCM Articles in Press. Published on 01-February-2017 as 10.1164/rccm.201612-2518LE Randomized double-blind controlled trial of roflumilast at acute exacerbations of COPD Authors: Alex J
More informationAirway Vista Background
Airway Vista 2013 Chronic Obstructive Airway Diseases Symposium Asan Medical Center, Seoul, South Korea When Should Macrolide Antibiotics be Prescribed to Prevent COPD Exacerbations in Usual Clinical Practice?
More informationAbstract. n engl j med 371;14 nejm.org october 2,
The new england journal of medicine established in 1812 october 2, 2014 vol. 371 no. 14 Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD Helgo Magnussen, M.D., Bernd Disse, M.D., Ph.D.,
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationAbbreviated Class Review: Chronic Obstructive Pulmonary Disease (COPD)
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Executive summary: Month/Year of Review: February
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationPatient characteristics Intervention Comparison Length of followup
ORAL MUCOLYTICS Ref ID: 2511 Bachh AA, Shah NN, Bhargava R et al. Effect oral N- in COPD - A randomised controlled trial. JK Practitioner. 2007; 14(1):12-16. Ref ID: 2511 RCT Single blind; unclear allocation
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationNEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE *Caroline Charles Scilink Medical Writing *Correspondence to scilink.mw@gmail.com Disclosure: Medical writing assistance
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More information16/06/2014. Introduzione I motivi di uno studio visti da un clinico. Riccardo Pistelli Università Cattolica - Roma
Introduzione I motivi di uno studio visti da un clinico Riccardo Pistelli Università Cattolica - Roma 1 GBD The Lancet Dicember 2012 Mortality rank GBD The Lancet Dicember 2012 YLDs 2 COPD: Mean Cost (MC)/patient
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJournal Club: Phosphodiesterase-4 Inhibitors Ron Balkissoon, MD, MSc, DIH, FRCPC 1
693 Journal Club: Phosphodiesterase-4 Inhibitors Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club: Phosphodiesterase-4 Inhibitors Ron Balkissoon, MD, MSc, DIH, FRCPC
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationOptum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,
ASTHMA CHART 1 Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year, 215-216 7 6 5 4 3 2 1 1 Controller medication 1 Rescue medication
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationD DAVID PUBLISHING. 1. Introduction
Journal of Health Science 2 (2014) 591-598 doi: 10.17265/2328-7136/2014.12.004 D DAVID PUBLISHING Comparative Efficacy and Safety of Two Formulations of Ipratropium Bromide (IB) HFA pmdi in Patients with
More information